Tinavi Medical Technologies Co.,Ltd. (SHA:688277)
China
· Delayed Price · Currency is CNY 23.70
-0.11 (-0.46%)
At close: Mar 9, 2026
SHA:688277 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 283.26 | 172.59 | 206.71 | 145.48 | 145.6 | Upgrade
|
| Other Revenue | - | 6.25 | 3.33 | 10.71 | 10.43 | Upgrade
|
| Revenue | 283.26 | 178.84 | 210.04 | 156.19 | 156.02 | Upgrade
|
| Revenue Growth (YoY) | 58.38% | -14.85% | 34.48% | 0.11% | 14.80% | Upgrade
|
| Cost of Revenue | - | 54.18 | 71.11 | 54.02 | 50.04 | Upgrade
|
| Gross Profit | 283.26 | 124.66 | 138.92 | 102.17 | 105.98 | Upgrade
|
| Selling, General & Admin | - | 188.11 | 217.47 | 164.98 | 140.57 | Upgrade
|
| Research & Development | - | 85.6 | 134.5 | 114.59 | 101.61 | Upgrade
|
| Other Operating Expenses | 444.08 | 2.48 | -3.84 | -0.3 | -1.27 | Upgrade
|
| Operating Expenses | 444.08 | 282.39 | 350.52 | 277.04 | 246.84 | Upgrade
|
| Operating Income | -160.83 | -157.73 | -211.6 | -174.87 | -140.86 | Upgrade
|
| Interest Expense | - | -9.14 | -6.43 | -3.95 | -3.35 | Upgrade
|
| Interest & Investment Income | - | 41.39 | 58.97 | 1.36 | 8.73 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 1.16 | 0.72 | 3.15 | -0.9 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.05 | -0.09 | -0.06 | -0.04 | -0.05 | Upgrade
|
| EBT Excluding Unusual Items | -160.87 | -124.42 | -158.39 | -174.36 | -136.43 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 0.05 | 0.09 | 0.1 | 0.63 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 5.39 | -0.03 | -0.05 | -0.17 | Upgrade
|
| Other Unusual Items | - | 19.44 | 7.65 | 30.15 | 31.32 | Upgrade
|
| Pretax Income | -160.87 | -99.55 | -150.69 | -144.16 | -104.65 | Upgrade
|
| Income Tax Expense | 23.16 | 21.58 | 10.61 | -31.82 | -22 | Upgrade
|
| Earnings From Continuing Operations | -184.03 | -121.13 | -161.3 | -112.34 | -82.65 | Upgrade
|
| Minority Interest in Earnings | - | - | 4.91 | 1.75 | 2.72 | Upgrade
|
| Net Income | -184.03 | -121.13 | -156.39 | -110.58 | -79.93 | Upgrade
|
| Net Income to Common | -184.03 | -121.13 | -156.39 | -110.58 | -79.93 | Upgrade
|
| Shares Outstanding (Basic) | 449 | 449 | 447 | 425 | 421 | Upgrade
|
| Shares Outstanding (Diluted) | 449 | 449 | 447 | 425 | 421 | Upgrade
|
| Shares Change (YoY) | 0.05% | 0.40% | 5.05% | 1.10% | 8.13% | Upgrade
|
| EPS (Basic) | -0.41 | -0.27 | -0.35 | -0.26 | -0.19 | Upgrade
|
| EPS (Diluted) | -0.41 | -0.27 | -0.35 | -0.26 | -0.19 | Upgrade
|
| Free Cash Flow | - | -135.34 | -391.53 | -147.1 | -316.42 | Upgrade
|
| Free Cash Flow Per Share | - | -0.30 | -0.88 | -0.35 | -0.75 | Upgrade
|
| Gross Margin | 100.00% | 69.70% | 66.14% | 65.42% | 67.93% | Upgrade
|
| Operating Margin | -56.78% | -88.20% | -100.74% | -111.96% | -90.28% | Upgrade
|
| Profit Margin | -64.97% | -67.73% | -74.46% | -70.80% | -51.23% | Upgrade
|
| Free Cash Flow Margin | - | -75.68% | -186.41% | -94.18% | -202.80% | Upgrade
|
| EBITDA | -128.93 | -125.83 | -187.6 | -157.52 | -130.04 | Upgrade
|
| EBITDA Margin | -45.52% | -70.36% | -89.32% | -100.85% | -83.35% | Upgrade
|
| D&A For EBITDA | 31.9 | 31.9 | 24 | 17.35 | 10.82 | Upgrade
|
| EBIT | -160.83 | -157.73 | -211.6 | -174.87 | -140.86 | Upgrade
|
| EBIT Margin | -56.78% | -88.20% | -100.74% | -111.96% | -90.28% | Upgrade
|
| Revenue as Reported | - | 178.84 | 210.04 | 156.19 | 156.02 | Upgrade
|
| Advertising Expenses | - | 1.59 | 2.27 | 1.91 | 2.36 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.